Since the excessive production of NO and resulting NO-derived metabolites elicit cellular toxicity and tissue damage, which contribute to the pathophysiology of a number of diseases, disorders and conditions, iNOS inhibitors have been investigated for the treatment of iNOS-mediated diseases and conditions including pain, hypotension, inflammation, arthritis and asthma [23]. This evidence concerns the gene NOS2 and asthma.